GEN Exclusives

More »

GEN News Highlights

More »
Apr 22, 2008

Simcere Buys 70% Stake in Wuhu Zhong Ren Pharmaceutical for $9.27M

  • Simcere Pharmaceutical plans to acquire a 70% equity interest in Wuhu Zhong Ren Pharmaceutical for RMB 64.82 million, or about $9.27 million. Simcere says that the transaction strengthens its focus on first-to-market branded generic and innovative new drugs as well as expands its anticancer portfolio.

    Zhong Ren Pharmaceutical is a Chinese drug manufacturer specializing in the production of sustained-release antitumor implants. Its key product is SinoFuan, which is reportedly the only sustained-release antitumor implant approved by the State Food and Drug Administration. It is used to treat cancers of the digestive tract.

    Simcere will leverage its marketing channels to distribute SinoFuan. Currently, the firm manufacturers Endu for stage III/IV non-small-cell lung cancer in China.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »